William Hays
Pulmonary Disease · Birmingham, ALNPI 1265473268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 226 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,544 and has fallen 92.6% since, to $189 in 2025. That places this record below the midpoint for pulmonary disease clinicians in AL, where the typical reported total is $3,082.
Across 226 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$587
- GSK$542
- Boehringer Ingelheim$395
- Genentech USA, Inc.$312
- Mallinckrodt Enterprises LLC$302
- Philips North America LLC$256
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,631100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $587 |
| GSK | 39 | $542 |
| Boehringer Ingelheim | 24 | $395 |
| Genentech USA, Inc. | 24 | $312 |
| Mallinckrodt Enterprises LLC | 16 | $302 |
| Philips North America LLC | 13 | $256 |
| Actelion Pharmaceuticals US, Inc. | 10 | $201 |
| Amgen | 13 | $180 |
| Regeneron Healthcare Solutions, Inc. | 7 | $135 |
| Merck | 8 | $133 |
| Jazz Pharmaceuticals Inc. | 4 | $83 |
| Mallinckrodt Hospital Products Inc. | 3 | $59 |
| Grifols USA, LLC | 3 | $55 |
| Pfizer | 3 | $50 |
| Insmed, Inc. | 3 | $45 |
| United Therapeutics Corporation | 2 | $43 |
| Bayer | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Novartis | 2 | $38 |
| Mylan Specialty L.p. | 2 | $36 |
| Cook Medical LLC | 2 | $23 |
| Electromed, Inc. | 2 | $22 |
| Sanofi | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$3,631 in reported general payments places this provider in the 50th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Birmingham
- Tejaswini KulkarniBirmingham$134K
- Amanda DenhamBirmingham$45K
- Bryan GarciaBirmingham$29K
- Steven RoweBirmingham$27K
- Peter MorrisBirmingham$25K
- Russell BeatyBirmingham$24K
- Jay HeideckerBirmingham$21K
- Jennifer TrevorBirmingham$19K
- Jason FainBirmingham$18K
- Jeffrey GarnerBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.